Now a Virtual Experience: 2020 ISPE Europe Annual Conference
Professional development and knowledge exchange in the pharmaceutical industry are more critical now than ever before, as the COVID-19 pandemic continues to have an unforeseeable global impact. It is essential to keep knowledge thriving to help drive the pharmaceutical industry forward and enhance patient health and safety worldwide.
We are pleased to announce that we are transforming Europe’s most comprehensive event on the latest innovations in pharmaceutical manufacturing to be fully digital: the 2020 ISPE Europe Annual Virtual Conference, taking place on 16–17 September 2020. As a bonus, delegates will receive access to the recording of all conference sessions for one year.
In addition to new content focused on industry response and issues associated with the COVID-19 pandemic, delegates will still benefit from robust, content-rich, interactive sessions covering critical topics like digitisation, the FDA’s continuous manufacturing draft guidance, aseptic processing, Annex 1, small molecules, and more.
It's our priority to make this the best and most informative ISPE Europe Annual Virtual Conference to date, and we remain excited to host you in September. We will update the event page in the coming weeks with additional information.
COVID-19 and After: Impact on Innovation, Production, Quality and Supply Chain
The 2020 ISPE Europe Annual Virtual Conference has four tracks focusing on:
Track 1: Facilities of the Future - Continuous manufacturing for oral solids and biotech; aseptic processing new improvements and technical innovations
Track 2: Pharma 4.0 – what is the way to implement the new operating model with industry cases, application of maturity models, digitisation, self-learning devices, plug and produce and a holistic control strategy
Track 3: Quality - validation, Annex 1, Annex 2, ICH Q13 and the FDA’s continuous manufacturing draft guidance, Annex 17 real time release testing and continuous verification
Track 4: New Trends in CQV and Impact on Project Delivery – small molecules, API, biopharmaceutical operations, key controls for being more flexible, more agile, more adaptive to changing product portfolio